Evidence map›Paper›PMID 42043261›Full record

Trial reportViruses2026

Immunogenicity and Safety of Biological E's Monovalent rDNA Hepatitis B Vaccine (BEVAC

Subhash Thuluva, Subbareddy Gunneri, Siddalingaiah Ningaiah, Vijay Yerroju, Rammohan Reddy Mogulla, Chirag Dhar, Kamal Thammireddy, Raju Esanakarra, Pradeep Nanjappa, Niranjana S Mahantshetti

Abstract readMulticenter StudyRandomized Controlled TrialEquivalence Trial
PubMed Full text at PMC Publisher
In one paragraph

Trial report in Viruses, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

10 authors.

Subhash ThuluvaBiological E Limited, Hyderabad 500 020, India.ORCID 0000-0002-9099-420X
Subbareddy GunneriBiological E Limited, Hyderabad 500 020, India.
Siddalingaiah NingaiahBiological E Limited, Hyderabad 500 020, India.ORCID 0009-0006-6116-4959
Vijay YerrojuBiological E Limited, Hyderabad 500 020, India.
Rammohan Reddy MogullaBiological E Limited, Hyderabad 500 020, India.
Chirag DharBiological E Limited, Hyderabad 500 020, India.
Kamal ThammireddyBiological E Limited, Hyderabad 500 020, India.ORCID 0009-0007-7614-4026
Raju EsanakarraBiological E Limited, Hyderabad 500 020, India.ORCID 0009-0008-2262-5454
Pradeep NanjappaDepartment of Pediatrics, Cheluvamba Hospital, Mysore Medical College & Research Institute, Mysore 570 001, India.
Niranjana S MahantshettiDepartment of Pediatrics, KLES Dr. Prabhakar Kore Hospital & Medical Research Centre, Belagavi 590 010, India.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Biological E's BEVAC

Indexed as

Hepatitis BHepatitis B VaccinesImmunogenicity, VaccineVaccines, DNAFemaleHepatitis B AntibodiesHumansIndiaInfantInfant, NewbornMaleSingle-Blind MethodVaccines, SyntheticHepatitis B AntibodiesHepatitis B VaccinesVaccines, DNAVaccines, SyntheticBEVAC®hepatitis B vaccineimmunogenicityneonatesnon-inferiorityphase IVrandomized trialsafety

Identifiers

PMID42043261
PMCPMC13120102

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.